Compounds > ne 21650
Page last updated: 2024-11-12

ne 21650

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

NE 21650: inhibits isopentenyl diphosphate isomerase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9994754
CHEMBL ID414849
MeSH IDM0413954

Synonyms (20)

Synonym
ne21650 ,
[2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl]phosphonic acid
gtpl3167
ne-21650
ne 21650
CHEMBL414849 ,
hydrogen [2-(2-azaniumylphenyl)-1-hydroxy-1-phosphonatoethyl]phosphonate
bdbm50173792
[2-(2-amino-phenyl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acid
2-(2-aminophenyl)-1-hydroxyethane-1,1-diyldiphosphonic acid
Q27087883
78xzc39fr5 ,
p,p'-(2-(2-aminophenyl)-1-hydroxyethylidene)bis(phosphonic acid)
phosphonic acid, p,p'-(2-(2-aminophenyl)-1-hydroxyethylidene)bis-
phosphonic acid, (2-(2-aminophenyl)-1-hydroxyethylidene)bis-
unii-78xzc39fr5
(2-(2-aminophenyl)-1-hydroxy-1-phosphonoethyl)phosphonic acid
427899-21-6
cid 9994754
AKOS040749008
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Farnesyl pyrophosphate synthaseHomo sapiens (human)IC50 (µMol)0.19620.00020.71099.3600AID318593; AID318594
Farnesyl pyrophosphate synthaseHomo sapiens (human)Ki0.03400.00010.21651.9000AID318593; AID318594
HTrypanosoma bruceiIC50 (µMol)2.10002.10002.10002.1000AID254970
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
cholesterol biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
farnesyl diphosphate biosynthetic processFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
protein bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
metal ion bindingFarnesyl pyrophosphate synthaseHomo sapiens (human)
dimethylallyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
geranyltranstransferase activityFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytosolFarnesyl pyrophosphate synthaseHomo sapiens (human)
cytoplasmFarnesyl pyrophosphate synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID349072Toxicity against human SF268 cells assessed as growth inhibition by broth microdilution method2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID340434Antimicrobial activity against Dictyostelium discoideum2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
AID349070Inhibition of the ATP-mediated HIV1 reverse transcriptase D67N/K70R/T215F/K219Q mutant catalyzed 3'-azido, 3'-deoxythymidine excision from AZT-terminated DNA primers2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID318594Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID349074Inhibition of the ATP-mediated HIV1 reverse transcriptase D67N/K70R/T215F/K219Q mutant catalyzed DNA synthesis2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID349073Toxicity against human NCI-H460 cells assessed as growth inhibition by broth microdilution method2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID318593Inhibition of human recombinant FPPS expressed in Escherichia coli BL212008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID318595Inhibition of bone resorption in rat assessed as phosphate2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
AID254970Inhibition of recombinant Trypanosoma brucei soluble vacuolar pyrophosphatase expressed in Escherichia coli2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Bisphosphonate inhibition of the exopolyphosphatase activity of the Trypanosoma brucei soluble vacuolar pyrophosphatase.
AID349071Toxicity against human MCF7 cells assessed as growth inhibition by broth microdilution method2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR investigation.
AID340428Inhibition of farnesyl diphosphate synthase at 7 nM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
AID1346854Human isopentenyl-diphosphate Delta-isomerase 1 (Lanosterol biosynthesis pathway)2002Biochemical and biophysical research communications, Jan-18, Volume: 290, Issue:2
Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diphosphoric acid
diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.		2.0410acyclic phosphorus acid anhydride;
phosphorus oxoacid		Escherichia coli metabolite
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		2.72301,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
incadronate
[no description available]		2.02101,1-bis(phosphonic acid)
pamidronate
[no description available]		2.0410phosphonoacetic acid
risedronic acid
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.		2.7330pyridines
2-(2-pyridyl)ethylidine-1,1-bisphosphonate
2-(2-pyridyl)ethylidine-1,1-bisphosphonate: inhibits hypercalciuria		2.0410
ibandronic acid
Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.		2.0410
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		2.44201,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
6-amino-1-hydroxyhexane-1,1-diphosphonate
6-amino-1-hydroxyhexane-1,1-diphosphonate: used for therapy of Paget's disease of bone & malignant hypercalcaemia		2.44201,1-bis(phosphonic acid)
ne 58051
NE 58051: inhibits tumor cell adhesion to extracellular matrices; structure in first source		2.4420
1-hydroxypentane-1,1-bisphosphonate
[no description available]		2.0210
cimadronate
cimadronate: increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source		2.0410
ne 10790
[no description available]		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
African Sleeping Sickness
[description not available]		02.0210
Trypanosomiasis, African
A disease endemic among people and animals in Central Africa. It is caused by various species of trypanosomes, particularly T. gambiense and T. rhodesiense. Its second host is the TSETSE FLY. Involvement of the central nervous system produces African sleeping sickness. Nagana is a rapidly fatal trypanosomiasis of horses and other animals.		02.0210